Novo Nordisk A/S (NYSE:NVO) rating reiterated by Cantor Fitzgerald

Novo Nordisk A/S (NYSE:NVO – Get a free report)The stock’s “overweight” rating was restated by research analysts at Cantor Fitzgerald in a report on Monday, Benzinga reports. They currently have a $160.00 target price on the stock. Cantor Fitzgerald’s target price would suggest a potential upside of 23.30% from the company’s previous close.

Several other brokerages have recently weighed in on NVO. Goldman Sachs Group started coverage on shares of Novo Nordisk A/S in a report on Thursday, May 30th. They issued a “buy” rating and a $156.00 target price on the stock. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Monday, August 19th. BMO Capital Markets dropped their target price on shares of Novo Nordisk A/S from $170.00 to $160.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. Finally, Argus raised their target price on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a research report on Monday, 10 June. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Moderate Buy” and an average price target of $145.17, according to MarketBeat .

See the latest Novo Nordisk A/S stock report

Novo Nordisk A/S price performance

Shares of NYSE:NVO opened at $129.76 on Monday. The company’s fifty day moving average price is $134.26 and its 200 day moving average price is $132.73. Novo Nordisk A/S has a 12-month low of $86.96 and a 12-month high of $148.15. The company has a debt-to-equity ratio of 0.46, a current ratio of 0.94, and a quick ratio of 0.75. The firm has a market cap of $582.30 billion, a P/E ratio of 44.74, a P/E/G ratio of 1.43 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO – Get Your Free Report ) last issued its quarterly earnings data on Wednesday, August 7th. The company reported $0.65 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.71 by ($0.06). Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. The business had revenue of $9.82 billion for the quarter, compared to analysts’ expectations of $9.91 billion. As a group, sell-side analysts predict that Novo Nordisk A/S will post 3.11 earnings per share for the current fiscal year.

Institutional inputs and outputs

Several institutional investors and hedge funds have recently made changes to their positions in the company. Aveo Capital Partners LLC purchased a new stake in Novo Nordisk A/S in the fourth quarter valued at $205,000. 9258 Wealth Management LLC boosted its holdings in shares of Novo Nordisk A/S by 4.0% during the fourth quarter. 9258 Wealth Management LLC now owns 2,513 shares of the company’s stock worth $260,000 after purchasing an additional 97 shares during the period. Rollins Financial boosted its holdings in shares of Novo Nordisk A/S by 10.4% during the fourth quarter. Rollins Financial now owns 3,894 shares of the company’s stock worth $403,000 after buying an additional 368 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Novo Nordisk A/S by 38.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 94,544 shares of the company’s stock worth $9,781,000 after purchasing an additional 26,067 shares during the period. Finally, Gryphon Financial Partners LLC acquired a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at $237,000. 11.54% of the shares are currently held by hedge funds and other institutional investors.

Novo Nordisk A/S company profile

(Get a free report)

Novo Nordisk A/S, together with its subsidiaries, is engaged in the research and development, manufacturing and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America and internationally. It operates in two segments, diabetes and obesity care and rare diseases.

Recommended articles

Get news and reviews for Novo Nordisk A/S Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Novo Nordisk A/S and related companies with MarketBeat.com’s FREE daily email newsletter.